Company Encyclopedia
View More
name
FRONTAGE
01521.HK
Frontage Holdings Corporation, a contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies. It offers drug discovery services comprising medicinal chemistry, pharmacology, and efficacy, as well as absorption, distribution, metabolism, and excretion (ADME) screening. The company also provides drug metabolism and pharmacokinetics (DMPK); safety and toxicology; early phase clinical services; and bioequivalence and related services, such as pharmacology, medical writing, and regulatory support. In addition, it offers pharmaceutical product development services, including intermediate and active pharmaceutical ingredient (API) synthesis, process and formulation development, and clinical trial material manufacturing.
697.22 B
01521.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Life Sciences Tools and ServicesIndustry
Industry Ranking12/14
Industry medianC
Industry averageB
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE1.14%D
    • Profit Margin1.52%C
    • Gross Margin27.90%C
  • Growth ScoreD
    • Revenue YoY-3.02%D
    • Net Profit YoY-37.34%D
    • Total Assets YoY-3.85%D
    • Net Assets YoY1.73%C
  • Cash ScoreB
    • Cash Flow Margin6597.39%A
    • OCF YoY-3.02%D
  • Operating ScoreC
    • Turnover0.45C
  • Debt ScoreB
    • Gearing Ratio37.27%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Frontage Holdings Delays Circular Dispatch for Major Transaction

    Frontage Holdings Corp. announced a delay in dispatching a circular for a major transaction involving a Share Transfer Agreement. Initially set for November 20, 2025, the dispatch is postponed to December 24, 2025, to finalize contents. The circular includes financial details and shareholder recommendations. Current analyst rating for HK:1521 is Hold with a HK$1.00 price target.

    Tip Ranks·
    HK
    01521
    -2.83%
    Tip Ranks·
    HK
    01521
    -2.83%

    FRONTAGE's revenue for the first three quarters is approximately USD 191.4 million, an increase of 0.2% year-on-year

    FRONTAGE announced that its revenue for the first three quarters ending September 30, 2025, was approximately USD 191.4 million, an increase of 0.2% year-on-year. The net profit was approximately USD 5.6 million, a significant increase compared to the same period last year. The adjusted net profit was approximately USD 12.6 million, an increase of 32.5% year-on-year. As of September 30, 2025, the group's unaudited consolidated net asset value was approximately USD 34.5 million

    Zhitong·
    HK
    01521
    -2.83%
    Zhitong·
    HK
    01521
    -2.83%

    Frontage Holdings Reports Significant Profit Growth in Q3 2025

    Frontage Holdings Corp. reported its Q3 2025 financial results, showing a revenue increase to approximately US$191.4 million for the nine months ending September 30, 2025. Net profit surged to US$5.6 million, up from US$0.2 million in 2024, with an adjusted net profit rise of 32.5% to US$12.6 million. The company operates in the pharmaceutical and biotechnology sector, providing drug development services. The current analyst rating for its stock (HK:1521) is a Hold with a price target of HK$1.00.

    Tip Ranks·
    HK
    01521
    -2.83%
    Tip Ranks·
    HK
    01521
    -2.83%

    Frontage Holdings Announces Major Acquisition to Expand Market Presence

    Frontage Holdings Corp. has announced a major acquisition valued at RMB270,000,000, involving the entire issued share capital of a target company through its subsidiary, Frontage Shanghai. This transaction will make the target company a wholly-owned subsidiary and consolidate its financial results into Frontage’s statements. The acquisition requires shareholder approval and the formation of an Independent Board Committee. The latest analyst rating for Frontage Holdings (HK:1521) is a Hold with a price target of HK$1.50. Current market cap stands at HK$2.65B.

    Tip Ranks·
    HK
    01521
    -2.83%
    Tip Ranks·
    HK
    01521
    -2.83%

    FRONTAGE plans to acquire Shanghai Guanhao Pharmaceutical Technology Co., Ltd. for 270 million yuan to enhance its global laboratory service capabilities

    FRONTAGE plans to acquire Shanghai Guanhao Pharmaceutical Technology Co., Ltd. for 270 million yuan, aiming to enhance its global laboratory service capabilities. This transaction involves FRONTAGE Shanghai, Hangzhou Tigermed, and its wholly-owned subsidiaries, with the target company becoming a wholly-owned subsidiary of FRONTAGE. After the acquisition, the financial performance of the target company will be included in FRONTAGE's financial statements. The company primarily engages in clinical trial technology services, and the transaction is expected to be completed by October 31, 2025

    Zhitong·
    HK
    01521
    -2.83%
    Zhitong·
    HK
    01521
    -2.83%
    Posts
    View More
    © 2025 Longbridge｜Disclaimer